Clinical Trial RTOG 0925
- Natural History of Postoperative Cognitive Function, Quality Of Life, and Seizure Control in Patients with Supratentorial Low-Risk Grade II Glioma
- Principal Investigator
- Jeffrey Raizer
- Status: CLOSED
- Study Type: Observation, QOL
- Protocol No:.RTOG 0925
- The purpose of this study is to understand the effects of a brain tumor and surgery on the participant's cognitive function (thinking abilities, memory), quality of life, and seizures.
- This is a clinical trial, a type of research study for patients with low-grade (slow growing) glioma brain tumors. Doctors use standard regimens of therapy for treating brain tumors. Treatment decisions are generally based on changes in the size of the tumor over time. However it may possible to assess other things such as brain function (thinking abilities, memory, etc.) to determine if changes in treatment are needed. In this study, doctors are hoping to understand the changes in brain function with the goal that in the future more personalized treatment for low grade gliomas may be developed.
Some of the eligibility criteria include:
- Participants must have low grade glioma brain tumor.
- Participants must be 18 or older.
- Participants must begin the study within 84 days of their most recent cancer surgery.
- Description of Treatment
- Participation in this study involves the following tests and activities over a five year period: testing that measures aspects of the participant's thinking function at study entry and then at 7 additional time points; completion of 3 questionnaires at study entry and 5 additional time points; and completion of a record of seizures by the participant.
- Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center
Find Related Clinical Trials
Browse by Disease Sites
Other Clinical Trials by Jeffrey Raizer
- A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96)(NSC #725085, Alliance IND#15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
- A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
- A Phase 2, Multicenter, Open-Label Study Of BGJ398 in Patients with Recurrent Resectable or Unresectable Glioblastoma
- Phase Ib/II multicenter study of buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma multiforme (GBM)
- An Open Label Phase 1b/2 Study of Orally Administered PLX3397 in Combination with Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
- A Phase 1/2 Study of SL-701, a Subcutaneously Injected Multivalent Glioma-Associated Antigen Vaccine, in Adult Patients with Recurrent Glioblastoma Multiforme
- Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
- A Phase II Study of the Efficacy of Hypofractionated Radiation Therapy with Bevacizumab and Temozolomide Followed by Maintenance Temozolomide and Bevacizumab for Recurrent High-Grade Gliomas
- A Phase I-II trial Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas BTTC09-01
- A Phase II Trial of Oral Pazopanib plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) without Prior Bevacizumab Exposure and (B) after Failing Prior Bevacizumab
- Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine & Cytarabine with and without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System Lymphoma
- Randomized Phase II of Concurrent Bevacizumab & Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma
last updated: 18-Apr-15 11:35 PM
Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.